Drug Trial Radar · NCT01061177
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Last checked: Nov 19, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,090
Actual
Start
May 2010
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.
Conditions
- CML in Chronic Phase
Interventions
NilotinibDrug
Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Molecular Response (MR4^0) at 18 MonthsTime frame: at 18 months
Locations
320 sites in 26 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Rankweil, Austria
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Wels, Austria, Austria
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Charleroi, Belgium
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Hasselt, Belgium
Novartis Investigative Site
Laken, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Roeselare, Belgium
Novartis Investigative Site
Verviers, Belgium
Novartis Investigative Site
Yvoir, Belgium
Novartis Investigative Site
Aalst, Belgium, Belgium
Novartis Investigative Site
Luxembourg, Luxembourg, Belgium
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Pleven, Bulgaria, Bulgaria
Novartis Investigative Site
Rijeka, Croatia
Novartis Investigative Site
Zagreb, Croatia
Novartis Investigative Site
Olomouc, CZE, Czechia
Novartis Investigative Site
Brno-Bohunice, Czech Republic, Czechia
Novartis Investigative Site
Hradec Králové, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Aarhus C, Denmark
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Tartu, Estonia
Novartis Investigative Site
HUS Helsinki, Finland
Showing 40 of 320 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.